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Background: Adenocarcinoma of the urinary bladder is a rare malignancy. Radical surgery is suggested as the best
available treatment for early-stage disease, but there is currently no consensus on standard chemotherapy regimen
for advanced stage. We assessed the feasibility and effect of neoadjuvant chemotherapy with gemcitabine and
cisplatin (GC) plus S-1 for patients with locally advanced primary adenocarcinomas of the urinary bladder.
Methods: Six patients with locally advanced urachal or non-urachal (n = 3, each) primary adenocarcinoma of the
bladder were treated from October 2010 to October 2013 at a single center. All the patients were treated with 3 cycles
(21d, each) of GC plus S-1 (gemcitabine, 1000 mg/m2, days 1 and 8; cisplatin, 70 mg/m2, day 2; and S-1, 50 mg bid, day
1-14). After neoadjuvant chemotherapy, patients with urachal cancer were treated with en bloc radical cystectomy and
umbilectomy; the remaining 3 patients were treated with cystectomy.
Results: All patients successfully completed the neoadjuvant chemotherapy without serious side effects. Two patients
were assessed as complete response, 2 as partial response, 1 as stable disease and 1 as progressive disease.
Conclusions: Despite the limitations of a small study population, the GC plus S-1 regimen for locally advanced primary
adenocarcinoma of the urinary bladder was effective, and facilitated the success of surgery to a certain extent. Short
follow-up time was also a limitation of our study. More studies are needed to evaluate the results.
Keywords: Neoadjuvant chemotherapy, Primary adenocarcinomas of bladder, SurvivalBackground
Primary adenocarcinomas of the bladder account for less
than 2% of primary bladder cancers, and are rarely en-
countered [1,2]. Primary adenocarcinomas of the urinary
bladder can be subdivided into urachal and non-urachal
adenocarcinoma. Radical surgery is considered the best
available treatment, but the 5-year survival rates (11%-
61%) have not been satisfactory [3]. Patients with urachal
adenocarcinoma often present with higher stage disease
because the disease arises out-side of the bladder and
causes fewer symptoms before its invasion of surround-
ing organs. For patients with locally advanced primary* Correspondence: 343463975@qq.com; caihong12006@gmail.com
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therapy can be a good option: it helps downstage the
cancer before radical surgery, eradicates potential
micrometastases, and may avoid local and distant fail-
ure [4,5]. However, primary adenocarcinomas of the
urinary bladder are so rare that experience of chemo-
therapy is limited [6]. The National Comprehensive
Cancer Network (NCCN; version 2.2014) suggests that
chemotherapy with methotrexate, vinblastine, doxorubicin,
and cisplatin (MVAC) is not effective for primary adeno-
carcinomas of the urinary bladder, and according to some
reports a 5-fluorouracil (5-FU)-based regimen should be
tried [6,7]. Furthermore, gemcitabine plus cisplatin (GC)
has proved viable as first-line chemotherapy for urothelial
(transitional) cell carcinoma with overall survival compar-
able to that of MVAC but with fewer side effects [8].
Herein, we report our experience in treating 6 cases ofis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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3 urachal and 3 non-urachal.
Methods
This prospective observational study was approved by the
Institutional Review Board of Nanjing Medical University,
Nanjing, China. Each patient provided written informed
consent before treatment. Six patients with pathologically
diagnosed locally advanced primary adenocarcinoma of
the bladder were treated between October 2010 and Octo-
ber 2013 at Affiliated Cancer Hospital of Jiangsu Province
of Nanjing Medical University. The patients’ demograph-
ics and clinical data were collected. All the pathology
gained through biopsy via cystoscopy was confirmed as
adenocarcinoma before chemotherapy. Computed tomog-
raphy of cranial, chest and abdomen was done to exclude
the metastatic adenocarcinoma. All patients were con-
firmed primary adenocarcinoma of the bladder at a locally
advanced stage, with clinical stage ≥T2, without distant
metastasis, and with or without lymph node metastasis.
All the patients were treated with GC plus S-1 chemother-
apy for 3 cycles, 21 d/cycle: gemcitabine, 1000 mg/m2,
days 1 and 8; cisplatin, 70 mg/m2, day 2; and S-1, 50 mg
bid, days 1-14. The adenocarcinomas were classified as as
urachal or non-urachal prior to surgery. Tumors were
considered urachal if the tumor was located at the dome
of the bladder rather than the anterior bladder wall, with
the most critical features being the presence of a sharp de-
marcation between the tumor and the surface epithelium,
and the exclusion of a primary adenocarcinoma elsewhere.
Patients with urachal bladder cancer were treated with en
bloc radical cystectomy and umbilectomy. Non-urachal
patients were treated with cystectomy after neoadjuvant
chemotherapy. The response of the target lesions to treat-
ment was evaluated by computed tomography scan, in ac-
cordance with the Response Evaluation Criteria In Solid
Tumors (RECIST 1.1) guidelines: complete response (dis-
appearance of target lesion); partial response (≥30% de-
crease in the sum of the longest diameter of the target
lesion, from baseline); stable disease (between a partial re-
sponse and progressive disease); and progressive disease
(≥20% increase in the sum of the longest diameter of theTable 1 Case summaries of 6 patients with primary adenocar
Patient Age Gender Symptom Tumor
1 71 Male Pain Non-urachal
2 68 Male Hematuria Non-urachal
3 79 Female Hematuria Non-urachal
4 67 Male Pain Urachal
5 51 Male Hematuria Urachal
6 49 Male Pain and hematuria Urachal
aAfter neoadjuvant chemotherapy; bprogression-free survival; cstill alive.target lesion, from nadir) [9]. The patients were followed,
beginning at diagnosis.
Results
Six patients were enrolled in this study: 5 men and 1
woman, aged 49 to 79 years (mean 62.5 y; Table 1).
Hematuria and lower abdominal pain were the most fre-
quently reported symptoms at presentation. Specifically,
4 patients presented with hematuria and 3 with lower
abdominal pain (1 patient with both symptoms). One, 3,
and 2 patients were in stages T2, T3, and T4, respectively.
One month after the 3 cycles of neoadjuvant chemother-
apy, 2, 2, 1, and 1 patient were evaluated as complete re-
sponse, partial remission, stable disease, and progressive
disease, respectively. No patient stopped chemotherapy
because of side effects. Three patients were judged to
have non-urachal adenocarcinoma. Two of these re-
ceived en bloc radical cystectomy and umbilectomy. One
patient refused surgery. The 3 patients with non-urachal
adenocarcinoma were treated by cystectomy. After sur-
gery, pathology confirmed pure primary adenocarcinoma
in 5 patients.
Four patients experienced grade 2 myelosuppression.
Three patients had transient elevated serum creatinine
(averaging 1.5-fold normal). Three patients had nausea,
vomiting, and loss of appetite. All the patients recovered
from the side effects after completion of chemotherapy.
Discussion
Adenocarcinoma of the urinary bladder is a rare malig-
nancy with a poor prognosis. Patient survival is similar to
that of muscle-invasive urothelial carcinoma [10]. Unlike
other cancers, there is currently no consensus regarding a
standard chemotherapy regime for adenocarcinoma of the
urinary bladder. In the present study, we used GC plus S-1
for neoadjuvant chemotherapy. Johnson et al. [11] reported
that adenocarcinomas of the urinary bladder have a clinical
behavior similar to that of urothelial (transitional) cell car-
cinoma of the bladder, and GC as first-line chemotherapy
for urothelial cell carcinoma has fewer side effects and
similar overall survival compared with MVAC. 5-FU is
widely used in the treatment of adenocarcinomas (such ascinomas of the urinary bladder
Stage Responsea PFS, mob Survival, mo
T3b Complete 3 7
T2b Partial >18 18c
T4b Stable disease 6 12
T3b Complete >20 20c
T3b Partial >10 10c
T4a Progressive disease >6 6c
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5-FU to treat urachal cancers, but continuous 5-FU infu-
sion has recently been replaced by S-1, to avoid some of
the inconveniences and adverse effects of 5-FU [12,13]. S-
1 is a novel oral Xuoropyrimidine derivative that consists
of tegafur, 5-chloro-2, 4-dihydropyrimidine (CDHP), and
potassium oxonate.
All the 6 patients of the present study received GC plus
S-1 for 3 cycles, and no patient failed to complete the cy-
cles because of side effects. The most severe side effect
was grade 2 myelosuppression such as leucopenia and
thrombocytopenia. This was resolved within 2 to7 days
after symptomatic treatment with granulopoietin. More
severe side effects can be treated by blood transfusion. No
patient suffered renal function impairment because of
chemotherapy. Three patients experienced transient ele-
vated serum creatinine (averaging 1.5-fold normal). How-
ever, this also returned to normal after the end of
treatment. Thus, the safety of this chemotherapy regime
was acceptable.
In the present study, we applied GC plus S-1. Two pa-
tients had a partial response, and 2, 1, and 1 patient had
complete response, stable disease, and progressive disease,
respectively. In contrast, a study conducted by the MD An-
derson Cancer Center (MDACC) used combinations of 5-
FU and cisplatin and reported a 33% response rate [7].
Thus, our results are encouraging. Several factors may con-
tribute to the difference in response rate. Firstly, the com-
position of patients is different. The patients in MDACC
report are pure with urachal cancers, while in our study,
NU adenocarcinoma patients are included. Secondly, the
differences in the predominant ethnicities of the study pop-
ulations (Houston, TX cf. Nanjing, China) may have influ-
enced the response rate to chemotherapy. Many studies
report that genetic polymorphisms exist in different races,
especially in drug-metabolizing enzymes, drug targets, and
drug receptors [14,15]. These genetic polymorphisms may
have contribution to the response rate. Compared with
western populations, the patients in China have more at-
tention from their family. Better food and family care may
encourage the nutrients and psychological healthy of pa-
tients. More importantly, adenocarcinomas of the urinary
bladder are rare and all studies are limited in the small
cases. The choice of chemotherapy regimens has been
based largely on case reports and single institution experi-
ences and the statistical power is limited.
After 3 cycles of neoadjuvant chemotherapy, 5 patients
received surgery. The surgeries were straightforward and
uneventful. Considering neoadjuvant chemotherapy may
lead to increased edema and adhesion of the bladder to
the surrounding tissue, increasing the difficulty of the
operation. However, no unusual bleeding or postoperative
infection was observed in our cases. Patient 1 rejected
surgery because he had no medical insurance and couldnot bear any further financial burden. This patient had
complete response after 3 cycles of chemotherapy, but after
3 months, the tumor recurred.
The majority of relevant studies have indicated that
tumor stage is a highly significant predictor of outcome
[16,17]. The shorter follow-up time, small case number,
and the heterogeneity of patient 1 (who refused surgery
and even other treatments) handicapped our analysis in
this study. However, our results are enough to warrant
further clinical studies with a larger number of patients
with primary adenocarcinomas of the urinary bladder, to
evaluate the efficacy of GC plus S-1 combination
chemotherapy for neoadjuvant chemotherapy, and even
for adjuvant chemotherapy.
Despite the limitations, the preliminary results of this
study show that chemotherapy with GC plus S-1 for pri-
mary adenocarcinomas of the urinary bladder is effective.
For patients at a locally advanced stage, this regimen ef-
fectively downstaged the tumor and may eradicate poten-
tial micrometastases, without increasing the difficulty of
surgery.
Conclusions
Chemotherapy with the GC plus S-1 regimen for patients
with primary adenocarcinomas of the urinary bladder is
effective. To a certain extent, neoadjuvant chemotherapy
facilitates surgery of patients at the locally advanced stage.
Our treatments should be investigated in a randomized
controlled trial to confirm these outcomes.
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